Recursion acquires Vium for drug discovery

By The Science Advisory Board staff writers

Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.

Vium's platform combines computer vision, machine learning, and sensor technologies to noninvasively collect and derive insights from digital biomarkers in preclinical in vivo research. The acquisition will augment Recursion's in vitro datasets and bolster its core technologies.

Financial terms of the acquisition were not disclosed.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?